193901-90-5
CHEMICAL AND PHYSICAL PROPERTIES
| Density | 1.1224 g/mL at 25 °C |
|---|---|
| Viscosity | 3.0 cP at 20 °C |
| Other Experimental Properties | Osmolarity: 825 mOsmol/kg water at 37 °C |
COMPUTED DESCRIPTORS
| Molecular Weight | 975.9 g/mol |
|---|---|
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 18 |
| Rotatable Bond Count | 18 |
| Exact Mass | 976.11312 g/mol |
| Monoisotopic Mass | 976.11312 g/mol |
| Topological Polar Surface Area | 270 Ų |
| Heavy Atom Count | 56 |
| Formal Charge | 0 |
| Complexity | 1130 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently-Bonded Unit Count | 6 |
| Compound Is Canonicalized | Yes |
PRODUCT INTRODUCTION
description
Gadofosveset Trisodium is the trisodium salt form of gadofosveset, an injectable, intravascular, amphiphilic gadolinium-based contrast agent (GBCA) used with magnetic resonance angiography (MRA) imaging. Gadofosveset is a stable gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA) chelate derivative with a diphenylcyclohexylphosphate group. Upon injection, gadofosveset binds reversibly to endogenous serum albumin which increases its intravascular retention time compared to non-protein binding contrast agents. The serum albumin binding also increases T1-relaxivity of gadofosveset. This produces an increase in signal intensity of blood, thereby enhancing the visualization of blood vessels upon MRA and may aid in the diagnosis of certain blood vessels and heart disorders.